[go: up one dir, main page]

NO20072602L - Anti-IL-22RA-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon - Google Patents

Anti-IL-22RA-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon

Info

Publication number
NO20072602L
NO20072602L NO20072602A NO20072602A NO20072602L NO 20072602 L NO20072602 L NO 20072602L NO 20072602 A NO20072602 A NO 20072602A NO 20072602 A NO20072602 A NO 20072602A NO 20072602 L NO20072602 L NO 20072602L
Authority
NO
Norway
Prior art keywords
antibodies
binding partners
methods
inflammation
antagonizing
Prior art date
Application number
NO20072602A
Other languages
English (en)
Norwegian (no)
Inventor
Stacey R Dillon
Wenfeng Xu
Joyce M Lehner
Wayne R Kindsvogel
Yasmin A Chandrasekher
Anthony W Siadak
Pallavur V Sivakumar
Margaret D Moore
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of NO20072602L publication Critical patent/NO20072602L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
NO20072602A 2004-10-22 2007-05-21 Anti-IL-22RA-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon NO20072602L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62155304P 2004-10-22 2004-10-22
PCT/US2005/037821 WO2006047249A1 (fr) 2004-10-22 2005-10-21 Anticorps anti-il-22ra et partenaires de liaison et methodes d'utilisation de ces anticorps et de ces partenaires de liaison pour le traitement de maladies inflammatoires

Publications (1)

Publication Number Publication Date
NO20072602L true NO20072602L (no) 2007-07-23

Family

ID=35871017

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072602A NO20072602L (no) 2004-10-22 2007-05-21 Anti-IL-22RA-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon

Country Status (21)

Country Link
US (5) US7537761B2 (fr)
EP (1) EP1812476B1 (fr)
JP (1) JP4898691B2 (fr)
KR (1) KR101238684B1 (fr)
CN (1) CN101198625A (fr)
AT (1) ATE474856T1 (fr)
AU (1) AU2005299809B2 (fr)
BR (1) BRPI0516975A (fr)
CA (1) CA2584157C (fr)
CY (1) CY1110843T1 (fr)
DE (1) DE602005022475D1 (fr)
DK (1) DK1812476T3 (fr)
EA (1) EA015706B1 (fr)
ES (1) ES2347672T3 (fr)
IL (2) IL182503A (fr)
MX (1) MX2007004770A (fr)
NO (1) NO20072602L (fr)
PT (1) PT1812476E (fr)
UA (1) UA96122C2 (fr)
WO (1) WO2006047249A1 (fr)
ZA (1) ZA200704125B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965704A (en) * 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
CA2418950A1 (fr) * 2000-08-08 2002-02-14 Zymogenetics, Inc. Recepteurs de cytokines zcytor 11 solubles
AU2004223836A1 (en) * 2003-03-24 2004-10-07 Zymogenetics, Inc. Anti-IL-20 antibodies and binding partners and methods of using in inflammation
WO2005052001A2 (fr) 2003-11-21 2005-06-09 Zymogenetics, Inc. Anticorps du recepteur anti-il-20 et partenaires de liaison et procedes d'utilisation dans l'inflammation
MX2007004770A (es) * 2004-10-22 2007-11-22 Zymogenetics Inc Anticuerpos anti-il-22ra y moleculas y metodos para usarlos en inflamacion.
CA2631961A1 (fr) * 2005-12-02 2007-11-08 Genentech, Inc. Compositions et methodes de traitement des maladies et troubles associes au signalement des cytokines portant sur les anticorps qui se lient a il-22
WO2011047153A1 (fr) * 2009-10-15 2011-04-21 President And Fellows Of Harvard College Procédés de modulation de l'auto-immunité
PH12012500924A1 (en) * 2009-11-19 2012-11-26 Merck Serono Sa Humanized antibodies against human il-22ra
CA2789061A1 (fr) 2010-02-26 2011-09-01 Henrik Parshad Compositions stables contenant des anticorps
RS66182B1 (sr) 2010-05-28 2024-12-31 Novo Nordisk As Stabilne višedozne kompozicije koje sadrže antitelo i konzervans
AU2012204574B2 (en) 2011-01-04 2017-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating age-related macular degeneration
PL2686347T3 (pl) 2011-03-16 2018-10-31 Argenx Bvba Przeciwciała przeciwko CD70
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
CN109328069B (zh) * 2016-04-15 2023-09-01 亿一生物医药开发(上海)有限公司 Il-22在治疗坏死性小肠结肠炎中的用途
EP3464357A1 (fr) 2016-05-24 2019-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions pharmaceutiques destinés au traitement d'infections pulmonaires bactériennes
GB201612337D0 (en) * 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
US20190317098A1 (en) * 2016-11-24 2019-10-17 Huvet Bio, Inc. Composition for diagnosis of diseases
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
CA3102391A1 (fr) 2018-06-05 2019-12-12 Bioatla, Inc. Anticorps anti-il-22, fragments d'anticorps, leurs immunoconjugues et utilisations correspondantes
CN110078832B (zh) * 2019-04-18 2021-12-14 江南大学 一类基于ZZ domain的二抗及其制备方法和应用
MX2023010238A (es) * 2021-03-02 2023-12-05 Dana Farber Cancer Inst Inc Métodos para tratar trastornos de glóbulos rojos.
WO2024184333A1 (fr) 2023-03-08 2024-09-12 Leo Pharma A/S Anticorps il-22r destiné à être utilisé dans le traitement de la dermatite atopique

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) * 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
EP0154316B1 (fr) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Lymphokine chimiquement modifiée et son procédé de préparation
NZ212437A (en) 1985-06-17 1992-06-25 Mark Philip Best Site-directed antibody conjugates, and their preparation
WO1989004838A1 (fr) * 1987-11-25 1989-06-01 Immunex Corporation Recepteurs d'interleukine-1
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5436155A (en) * 1991-12-31 1995-07-25 Arch Development Corporation Isolated DNA encoding a somatostatin receptor
US5789192A (en) 1992-12-10 1998-08-04 Schering Corporation Mammalian receptors for interleukin-10 (IL-10)
ATE486937T1 (de) 1996-07-12 2010-11-15 Genentech Inc Chimärische heteromultimerische adhesine
US5843697A (en) 1996-07-17 1998-12-01 University Of Medicine And Dentistry Of New Jersey Cells expressing IL-10 receptor and the CRFB4 gene product, an IL-10 receptor accessory protein
US5985614A (en) * 1996-08-30 1999-11-16 Human Genome Sciences, Inc. Polynucleotides encoding interleukin-19
US5945511A (en) * 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6486301B1 (en) * 1997-07-16 2002-11-26 Human Genome Sciences, Inc. Interleukin-20
EP1012260A4 (fr) 1997-07-16 2001-05-09 Human Genome Sciences Inc Interleukine-20
US5965704A (en) 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
CA2298439A1 (fr) * 1997-08-06 1999-02-18 Zymogenetics, Inc. Homologues de lipocaline
US6551799B2 (en) 1999-12-07 2003-04-22 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US6576743B1 (en) * 1997-11-26 2003-06-10 Zymogenetics, Inc. Mammalian cytokine-like polypeptide-10
CA2312000C (fr) 1997-11-26 2013-03-26 Zymogenetics, Inc. Polypeptide 10 de type cytokine mammifere
PT1047781E (pt) 1998-01-23 2004-11-30 Immunex Corp Receptores de il-18
JP2002505879A (ja) 1998-03-09 2002-02-26 シェーリング コーポレイション ヒトレセプタータンパク質；関連する試薬および方法
EP1490386B1 (fr) 1998-03-10 2008-08-13 Genentech, Inc. Nouveau polypeptide et acides nucleiques lui codant
US6197582B1 (en) 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
US6982320B2 (en) 1998-03-19 2006-01-03 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
AU5203199A (en) 1998-05-26 1999-12-13 Procter & Gamble Company, The Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system
AU5728999A (en) 1998-07-28 2000-02-21 Micromet Ag Heterominibodies
NZ531664A (en) 1998-09-01 2005-07-29 Genentech Inc Pro1317 polypeptides and sequences thereof with homology to the semaphorin B glycoprotein family
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6274710B1 (en) * 1998-10-26 2001-08-14 Ludwig Institute For Cancer Research Antibodies which specifically bind T Cell inducible factors (TIFs)
CN1238367C (zh) 1998-10-26 2006-01-25 路德维格癌症研究院 分离的编码t细胞诱导因子(tif)的核酸分子,其编码蛋白及其应用
AU2222700A (en) 1998-12-31 2000-07-31 Millennium Pharmaceuticals, Inc. Class ii cytokine receptor-like proteins and nucleic acids encoding them
BR0010097A (pt) 1999-04-28 2002-02-13 Genetics Inst Polinucleotìdeo isolado; célula hospedeira; processo para a produção de uma proteìna codificada pelo polinucleotìdeo; proteìna; composição; e; anticorpo
EP1179066A2 (fr) 1999-05-19 2002-02-13 Incyte Genomics, Inc. Molecules de signalisation extracellulaires
AU5047600A (en) 1999-05-27 2000-12-18 Schering Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
EP1208195A2 (fr) 1999-06-15 2002-05-29 Genentech Inc. Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
AU2883700A (en) 1999-06-23 2001-01-09 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001004304A1 (fr) 1999-07-07 2001-01-18 Zymogenetics, Inc. Recepteur de cytokine humaine
CA2380355A1 (fr) 1999-09-01 2001-03-08 Genentech, Inc. Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
EP1230368A2 (fr) 1999-11-18 2002-08-14 Schering Corporation Proteines de recepteurs mammaliens, reactifs et procedes s'y rapportant
US6897292B2 (en) 1999-12-03 2005-05-24 Zymogenetics, Inc. Human cytokine receptor
DE60043944D1 (de) 1999-12-23 2010-04-15 Zymogenetics Inc Zytokin zcyt018
WO2001046232A2 (fr) 1999-12-23 2001-06-28 Zymogenetics, Inc. Recepteur soluble de l'interleukine-20
US6610286B2 (en) * 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
DE60030769T2 (de) 1999-12-23 2007-10-25 Zymogenetics, Inc., Seattle Verfahren zur behandlung von entzündungen
NZ523122A (en) 2000-06-22 2004-06-25 Smithkline Beecham Corp Polypeptides and polynucleotides and methods of identifying agonists and antagonists in relation to treatment of diseases
JP2002015498A (ja) 2000-06-29 2002-01-18 Fujitsu Ltd センス電流の設定方法
CA2418950A1 (fr) 2000-08-08 2002-02-14 Zymogenetics, Inc. Recepteurs de cytokines zcytor 11 solubles
MXPA03002049A (es) 2000-09-08 2003-07-24 Schering Corp Genes de mamiferos: reactivos y metodos relacionados.
EP1803733B1 (fr) * 2000-09-15 2010-03-10 ZymoGenetics, Inc. Polypeptides comprenant le domaine extracellulaire de IL-20RA et / ou IL-20RB
US7268223B2 (en) 2000-09-22 2007-09-11 Wyeth Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
US20030022827A1 (en) * 2000-09-25 2003-01-30 Bertram Weiss Three new members of the cytokine receptor family class 2
EP1191035A3 (fr) 2000-09-25 2002-04-17 Schering Aktiengesellschaft Trois membres de la famille des recepteurs de la cytokine de classe II
WO2002066647A2 (fr) 2001-01-12 2002-08-29 Genetics Institute, Llc. Recepteur de cytokine de type 2 et acides nucleiques codant ce recepteur
WO2002058724A2 (fr) 2001-01-26 2002-08-01 Eli Lilly And Company Utilisation de lp82 pour traiter les problemes de poids
BR0207528A (pt) 2001-02-23 2006-01-17 Inst Genetics Llc Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo
CA2433933A1 (fr) 2001-02-28 2002-09-12 Eli Lilly And Company Utilisation de lp82 pour traiter les troubles hematopoietiques
US6875845B2 (en) * 2001-03-02 2005-04-05 Zymogenetics, Inc. Mouse cytokine receptor
US20040086908A1 (en) 2002-03-07 2004-05-06 Chandrasekher Yasmin A. Soluble heterodimeric cytokine receptor
IL157726A0 (en) * 2001-03-09 2004-03-28 Zymogenetics Inc Soluble heterodimeric cytokine receptor
JP2005503765A (ja) 2001-03-27 2005-02-10 ザイモジェネティクス，インコーポレイティド ヒトサイトカイン受容体
PT2163256E (pt) 2001-05-11 2015-11-20 Ludwig Inst For Cancer Res Ltd Proteínas de ligação específica e suas utilizações
EP1439850A4 (fr) 2001-10-22 2006-05-03 Lilly Co Eli Proteines solubles inhibant les voies de transduction du signal de la cytokine
DE10154579A1 (de) 2001-11-07 2003-05-28 Medigene Ag Topikale Verwendung von Cytokinen und Chemokinen zur Behandlung von viralen oder mykotischen Hauterkrankungen oder Tumorerkrankungen
CA2467723C (fr) 2001-12-17 2011-09-27 Zymogenetics, Inc. Methode de traitement du cancer du col de l'uterus
US20040236075A1 (en) 2002-07-24 2004-11-25 Laure Dumoutier Novel glass II cytokine receptors, and uses thereof
AU2004223836A1 (en) 2003-03-24 2004-10-07 Zymogenetics, Inc. Anti-IL-20 antibodies and binding partners and methods of using in inflammation
WO2005052001A2 (fr) * 2003-11-21 2005-06-09 Zymogenetics, Inc. Anticorps du recepteur anti-il-20 et partenaires de liaison et procedes d'utilisation dans l'inflammation
MX2007004770A (es) * 2004-10-22 2007-11-22 Zymogenetics Inc Anticuerpos anti-il-22ra y moleculas y metodos para usarlos en inflamacion.
PH12012500924A1 (en) * 2009-11-19 2012-11-26 Merck Serono Sa Humanized antibodies against human il-22ra

Also Published As

Publication number Publication date
ATE474856T1 (de) 2010-08-15
US20130315919A1 (en) 2013-11-28
MX2007004770A (es) 2007-11-22
IL182503A0 (en) 2007-09-20
JP2008517922A (ja) 2008-05-29
DE602005022475D1 (de) 2010-09-02
IL207146A0 (en) 2010-12-30
AU2005299809B2 (en) 2010-12-02
US7537761B2 (en) 2009-05-26
IL207146A (en) 2012-06-28
US20100210825A1 (en) 2010-08-19
US7871616B2 (en) 2011-01-18
US8124088B2 (en) 2012-02-28
US20090220519A1 (en) 2009-09-03
CA2584157A1 (fr) 2006-05-04
EA200700916A1 (ru) 2007-10-26
CN101198625A (zh) 2008-06-11
UA96122C2 (ru) 2011-10-10
CY1110843T1 (el) 2015-06-10
US20060141582A1 (en) 2006-06-29
PT1812476E (pt) 2010-11-08
EA015706B1 (ru) 2011-10-31
EP1812476B1 (fr) 2010-07-21
KR101238684B1 (ko) 2013-03-04
CA2584157C (fr) 2014-10-14
AU2005299809A2 (en) 2006-05-04
KR20070084486A (ko) 2007-08-24
DK1812476T3 (da) 2010-10-25
US8536309B2 (en) 2013-09-17
HK1110333A1 (en) 2008-07-11
ZA200704125B (en) 2008-09-25
WO2006047249A1 (fr) 2006-05-04
US20120156210A1 (en) 2012-06-21
ES2347672T3 (es) 2010-11-03
JP4898691B2 (ja) 2012-03-21
BRPI0516975A (pt) 2008-09-30
EP1812476A1 (fr) 2007-08-01
IL182503A (en) 2012-01-31
AU2005299809A1 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
NO20072602L (no) Anti-IL-22RA-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon
NO20054892D0 (no) Anti-IL-22RA-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon
NO20070153L (no) Loselig zcytorl4, anti-zcytorl4-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon
WO2005052000A3 (fr) Anticorps et partenaires de liaison anti-il 20 et procedes d'utilisation dans l'inflammation
DK1931697T3 (da) IL-17A og IL-17F-antagonister og fremgangsmåder til anvendelse af disse
WO2008039553A8 (fr) Il-17rcx4 soluble et procédés d'utilisation dans l'inflammation
WO2007106769A3 (fr) Anticorps se liant à la fois avec il-17a et il-17f et procédés d'utilisation
EP1603949B8 (fr) Anticorps diriges contre le recepteur humain de l'il-21 et utilisations correspondantes
EA200870274A1 (ru) ПЕПТИДЫ, БЛОКИРУЮЩИЕ СВЯЗЫВАНИЕ IgG C FcRn
WO2008133684A8 (fr) Anticorps qui se lient à la fois à il-17a et il-17f et leurs procédés d'utilisation
MX337778B (es) Anticuerpos contra il-22 humana y usos para los mismos.
NO20083697L (no) Fremgangsmater for anvendelse av antistoffer mot human IL-22
WO2006086396A3 (fr) Anticorps et partenaires de liaison anti-il-20, anti-il-22 et anti-il-22ra, et methodes d'utilisation de ces anticorps et partenaires de liaison dans des processus inflammatoires
EA200700823A1 (ru) Растворимый zcytor21, анти-zcytor21 антитела и связывающие партнёры и способы применения при воспалении
EA200600314A1 (ru) Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях
WO2007076422A3 (fr) Anticorps contre la proteine de liaison interleukine 22 et son utilisation dans le traitement de troubles metaboliques

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application